SAN DIEGO, Aug. 29, 2019 (GLOBE NEWSWIRE) — Synthorx, Inc. (NASDAQ: THOR), a clinical-stage biotechnology company developing optimized therapeutics for cancer and autoimmune disorders, today announced the Company will present at the H.C. Wainwright 21st Annual Global Investment Conference on Monday, September 9 at 10:25 a.m. ET in New York, NY.
News
Synthorx to Present at the European Society for Medical Oncology (ESMO) 2019 Congress
SAN DIEGO, Sept. 23, 2019 (GLOBE NEWSWIRE) — Synthorx, Inc. (NASDAQ: THOR), a clinical-stage biotechnology company developing optimized therapeutics for cancer and autoimmune disorders, today announced that preclinical data for immuno-oncology produ… […]
News
Synthorx Reports Third Quarter Financial Results
SAN DIEGO, Nov. 05, 2019 (GLOBE NEWSWIRE) — Synthorx, Inc. (Nasdaq: THOR), a clinical-stage biotechnology company developing optimized therapeutics for cancer and autoimmune disorders, today reported financial results and provided a business update … […]
News
Synthorx Reports Third Quarter Financial Results
SAN DIEGO, Nov. 05, 2019 (GLOBE NEWSWIRE) — Synthorx, Inc. (Nasdaq: THOR), a clinical-stage biotechnology company developing optimized therapeutics for cancer and autoimmune disorders, today reported financial results and provided a business update … […]
